Status:
ACTIVE_NOT_RECRUITING
The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
Lead Sponsor:
Mebo Research, Inc.
Collaborating Sponsors:
Aurametrix
Conditions:
COVID-19 Vaccines
Eligibility:
All Genders
18+ years
Brief Summary
During the study, members of different online and offline communities will be followed post COVID-19 vaccination. Injection-site (local) and systemic reaction data will be assessed on vaccination day...
Detailed Description
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a Public Health Emergency of International Concern in January 2020 and upgraded to pandemic in March 2020. Fir...
Eligibility Criteria
Inclusion
- Individuals 18 or older at the time of consent
- Intention to vaccinate and of being available for entire study period
Exclusion
- Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.
Key Trial Info
Start Date :
January 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 5 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04832932
Start Date
January 5 2021
End Date
January 5 2025
Last Update
January 26 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
MEBO Research, Inc
Miami, Florida, United States, 33175
2
Kahite
Vonore, Tennessee, United States, 37885
3
Gabashvili
Tbilisi, Georgia
4
MEBO Research Africa
Kilifi, Kenya, 8 010